Skip to main content

What's new?

We are delighted to announce Cancer & Metabolism's first Impact Factor is 5.033!


Thank you to our Editors-in-Chief Dr. Michael Pollak and Dr. Matthew G. Vander Heiden for their hard work and to all those who support this journal.


The current Eigenfactor Score is 0.33812 and the Immediacy Index is 0.583.


Aims and scope

Cancer & Metabolism welcomes studies on all aspects of the relationship between cancer including molecular biology and genetics. The journal is indexed in DOAJ, Emerging Sources Citation Index (ESCI), PubMed, and PubMed Central.

Learn more

Editorial Board

Dr. Michael Pollak, co-Editor-in-Chief

Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.

"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."

New Content ItemDr. Matthew G. Vander Heiden, co-Editor-in-Chief

Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C).


Associate Editors:
Kivanc BirsoyThe Rockefeller University, USA
Kevin BrindleUniversity of Cambridge, UK
Navdeep ChandelNorthwestern University, USA
Teresa FanMarkey Cancer Center, USA
Lydia Finley, Memorial Sloan Kettering Cancer Center, USA 
Rudolf KaaksGerman Cancer Research Center, Germany
Richard G. KibbeyYale University School of Medicine, USA
Costas LyssiotisUniversity of Michigan, USA
Rachel Perry, Yale University School of Medicine, USA
Reuben Shaw, The Salk Institute for Biological Studies, USA
Julie St-Pierre, University of Ottawa, Canada
Alexei VazquezUniversity of Glasgow, UK
Kathryn Wellen, University of Pennsylvania, USA

Editorial Board Members:
Abass AlaviUniversity of Pennsylvania School of Medicine, USA
Lewis Cantley, Weill Cornell Medical College, USA
Peter CarmelietVesalius Research Center, Belgium
Gina DeNicola, Moffitt Cancer Center, USA
Robert Gatenby, Moffitt Cancer Center, USA
Kun-Liang GuanUniversity of  California, USA



 


Andrew LaneMarkey Cancer Center, USA
Sophia Lunt, Michigan State University, USA
Christian Metallo, University of California, San Diego Department of Bioengineering, USA
Gordon Mills, University of Texas M. D. Anderson Cancer Center, USA
Thales Pappagiannokopoulos, NYU Grossman School of Medicine, USA
Jacques PouyssegurInstitute of Research on Cancer and Aging, France
Joshua Rabinowitz, Princeton University, USA
Peter RatcliffeNuffield Department of Clinical Medicine, UK
Jeffrey Rathmell, Duke University, USA
Jared RutterUniversity of Utah School of Medicine, USA
David Sabatini, Whitehead Institute for Biomedical Research, USA
Gregg Semenza, Johns Hopkins University School of Medicine, USA
Celeste Simon, University of Pennsylvania School of Medicine, USA
Bert Vogelstein, Johns Hopkins University School of Medicine, USA
Karen Vousden, Beatson Institute for Cancer Research, UK
Eileen White, The Cancer Institute of New Jersey, USA

Articles

Chi Van Dang, Editor Emeritus

Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.

"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."

Impact of COVID-19

COVID-19 © elipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our usual peer review process. We thank referees for their continued support in these challenging times and ask authors for their patience and understanding.

Thumbnail image by Felipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license.

Annual Journal Metrics

  • Speed
    65 days to first decision for reviewed manuscripts only
    59 days to first decision for all manuscripts
    135 days from submission to acceptance
    35 days from acceptance to publication

    Citation Impact

    5.033 - 2 Year Impact Factor
    0.583 - Immediacy Index

    Usage 
    140,853 Downloads
    210 Altmetric Mentions